Cefuroxim Axetil 250 mg
| Composition | Cefuroxim Axetil 250 mg |
|---|---|
| Packing | 10x10 Alu/Alu |
| MRP | ₹ 2800 |
| Dosage Form | Tablets |
Stemcef-250 is an antibiotic tablet containing Cefuroxime Axetil 250 mg, a second-generation cephalosporin antibiotic. It is prescribed for the treatment of a wide range of bacterial infections affecting the respiratory tract, urinary system, skin, and other areas. Cefuroxime Axetil is an orally administered prodrug that is converted to the active Cefuroxime in the body.
Stemcef-250 is valued for its effectiveness against both common gram-positive and gram-negative bacteria and its resistance to many beta-lactamase enzymes produced by certain bacteria, giving it a broader spectrum of activity than many first-generation cephalosporins.
This medicine is commonly used for:
Cefuroxime Axetil 250 mg is indicated for mild to moderate infections caused by susceptible organisms including acute bacterial exacerbations of chronic bronchitis, uncomplicated community-acquired pneumonia, acute sinusitis, acute otitis media, pharyngitis/tonsillitis, uncomplicated urinary tract infections, uncomplicated skin and soft tissue infections, and early Lyme disease. It demonstrates activity against Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis, Staphylococcus aureus, and various Enterobacteriaceae.
Cefuroxime in Stemcef-250 works by attacking the outer cell wall of bacteria, which bacteria need to survive. It prevents the bacteria from building and maintaining this wall properly, causing them to break apart and die. It is effective against a broad range of common bacteria that cause respiratory, urinary, and skin infections.
Cefuroxime Axetil is an ester prodrug hydrolysed by intestinal and hepatic esterases to Cefuroxime, a bactericidal beta-lactam antibiotic. Cefuroxime binds to penicillin-binding proteins (PBPs) on the bacterial cell membrane, inhibiting transpeptidation and cross-linking of peptidoglycan strands essential for cell wall integrity. The resultant structural weakness leads to osmotic lysis and cell death. Its beta-lactamase stability makes it effective against many resistant organisms compared to first-generation cephalosporins.
Cefuroxime was specifically engineered to be more resistant to the enzyme (beta-lactamase) that bacteria use to destroy penicillin-related antibiotics — this is why it can treat infections caused by bacteria that have become resistant to older antibiotics.
Stemcef-250 is typically taken with food to improve absorption and reduce stomach upset, as prescribed by your doctor. Take at evenly spaced intervals and complete the full prescribed course even if you feel better. Never self-medicate or share antibiotics.
Always follow the dosage and schedule advised by your doctor — this is general guidance only.
Common side effects include diarrhoea, nausea, stomach discomfort, and headache. Some people may develop a mild skin rash. Rarely, Clostridium difficile-associated diarrhoea may occur with any antibiotic. Tell your doctor if any side effect is severe or persistent.
Cephalosporin antibiotics are only for serious hospital infections.
Cefuroxime (as in Stemcef-250) is widely used in outpatient settings for common community infections like sinusitis, bronchitis, and urinary tract infections.
Feeling better after two days means you can stop the antibiotic.
Stopping early allows surviving bacteria to regrow and become resistant. Always complete the full prescribed course.